For older adults with acute myeloid leukemia, treatment has long meant a grinding choice: endure intensive chemotherapy in a hospital or infusion center, or accept a less effective path forward. On Tuesday, the U.S. Food and Drug Administration approved a combination that could reshape that calculus entirely. Taiho Oncology's Inqovi—a pill combining decitabine and cedazuridine—plus the oral drug venetoclax has become the first and only all-oral hypomethylating regimen approved for newly diagnosed AML patients age 75 and older or those ineligible for intensive chemotherapy.
This approval matters because it breaks the treatment infrastructure's hold on patient care. Until now, patients in this category largely depended on parenteral hypomethylating agents that required frequent clinic visits and hospital time—a burden that compounds for elderly patients managing multiple conditions and caregivers juggling medical appointments. An oral option that patients can potentially take at home represents not just medical progress, but a shift in how treatment integrates into daily life.
The regulatory decision rests on results from the Phase II ASCERTAIN-V study, which followed patients receiving the Inqovi-venetoclax combination. Forty-two patients achieved complete remission, representing a 41.6% response rate. The median time to remission reached two months, and notably, the median duration of remission was not reached—meaning some patients sustained their remission beyond the study's observation window. These numbers offer genuine hope for a population that has historically faced grim odds.
The safety profile, however, demands frank acknowledgment. Serious adverse reactions occurred in 82% of patients receiving the combination, reflecting the serious nature of AML treatment itself. The most common severe complications included febrile neutropenia in 31% of patients, sepsis in 22%, pneumonia in 15%, bacterial or viral infection in 10%, hemorrhage in 9%, and dyspnea in 6%. Fatal adverse reactions occurred in 8% of patients. These figures underscore that the approval is not a free pass but a calculated trade-off: meaningful survival gains balanced against real risks.
Yet for this specific patient population—elderly or medically complex adults who cannot tolerate aggressive hospital-based chemotherapy—the equation shifts. The ability to manage treatment from home, to reduce the logistical strain on families already stretched thin, carries its own weight. Harold Keer, M.D., Ph.D., Taiho Oncology's chief medical officer, framed it plainly: this approval "marks an important step forward in expanding how treatment can be delivered for this patient population, offering an all-oral option that can potentially reduce the overall treatment burden associated with receiving treatment in hospitals or infusion centers."
The approval opens a new pathway for thousands of patients annually. Acute myeloid leukemia remains a diagnosis that changes everything—for patients confronting mortality and for families suddenly navigating oncology's complexity. When treatment can happen at the kitchen table rather than the infusion center, when a daily pill replaces weekly hospital visits, something shifts in the patient's sense of agency and normalcy. This oral combination represents medicine remembering that how we treat people matters as much as what we treat them with.